Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod in Active Rheumatoid Arthritis
NCT01554917Phase 4Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- May 2012
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iguratimod in rheumatoid arthritis (RA), sponsored by Simcere Pharmaceutical Group. Primary endpoints: American College of Rheumatology 20% response criteria at week 24 and Incidence of adverse events up to 28 weeks. Started May 2012; status: completed.
02
Drugs
iguratimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01554917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01554917.